DA
NVO

Dillon & Associates’s Novo Nordisk NVO Stock Holding History

Dillon & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.63M Sell
206,349
-94,849
-31% -$4.49M 1.05% 26
2025
Q4 		$15.4M Sell
301,198
-10,702
-3% -$547K 1.98% 14
2025
Q3 		$17.2M Buy
311,900
+8,017
+3% +$469K 2.21% 12
2025
Q2 		$21M Buy
303,883
+8,769
+3% +$596K 2.85% 9
2025
Q1 		$20.4M Buy
295,114
+7,638
+3% +$631K 3.03% 8
2024
Q4 		$24.7M Buy
287,476
+4,059
+1% +$439K 3.43% 6
2024
Q3 		$33.7M Buy
283,417
+1,271
+0.5% +$170K 4.75% 3
2024
Q2 		$40.3M Buy
282,146
+4,319
+2% +$572K 5.87% 3
2024
Q1 		$35.6M Buy
277,827
+3,819
+1% +$455K 5.59% 3
2023
Q4 		$28.2M Sell
274,008
-8,469
-3% -$838K 5.12% 4
2023
Q3 		$25.7M Buy
282,477
+9,001
+3% +$793K 4.95% 5
2023
Q2 		$22.2M Sell
273,476
-6,238
-2% -$510K 4.08% 6
2023
Q1 		$22.2M Sell
279,714
-9,718
-3% -$689K 4.41% 5
2022
Q4 		$19.5M Sell
289,432
-284
-0.1% -$16.7K 4.23% 5
2022
Q3 		$14.5M Sell
289,716
-640
-0.2% -$34.3K 3.36% 10
2022
Q2 		$16.1M Sell
290,356
-1,326
-0.5% -$73.6K 3.63% 8
2022
Q1 		$16.2M Sell
291,682
-2,420
-0.8% -$124K 3.07% 10
2021
Q4 		$16.5M Sell
294,102
-560
-0.2% -$30.3K 2.87% 12
2021
Q3 		$14.1M Sell
294,662
-168
-0.1% -$8.12K 2.71% 13
2021
Q2 		$12.4M Sell
294,830
-2,582
-0.9% -$100K 2.42% 16
2021
Q1 		$9.96M Buy
297,412
+8,510
+3% +$303K 2.13% 20
2020
Q4 		$10.1M Buy
288,902
+8,718
+3% +$301K 2.2% 20
2020
Q3 		$9.67M Buy
280,184
+12,614
+5% +$420K 2.33% 18
2020
Q2 		$8.7M Buy
267,570
+764
+0.3% +$24.4K 2.35% 18
2020
Q1 		$8M Buy
266,806
+7,926
+3% +$236K 2.69% 13
2019
Q4 		$7.51M Sell
258,880
-3,180
-1% -$88.1K 2.1% 21
2019
Q3 		$6.81M Sell
262,060
-160
-0.1% -$4.05K 2.07% 23
2019
Q2 		$6.69M Sell
262,220
-1,728
-0.7% -$42.7K 2.07% 23
2019
Q1 		$6.86M Sell
263,948
-1,850
-0.7% -$45.5K 2.23% 21
2018
Q4 		$6.11M Sell
265,798
-13,560
-5% -$301K 2.33% 18
2018
Q3 		$6.57M Sell
279,358
-5,606
-2% -$137K 2.17% 18
2018
Q2 		$6.55M Sell
284,964
-422
-0.1% -$10K 2.42% 16
2018
Q1 		$6.99M Sell
285,386
-600
-0.2% -$15.8K 2.7% 13
2017
Q4 		$7.72M Buy
285,986
+100
+0% +$2.54K 2.91% 13
2017
Q3 		$6.86M Buy
285,886
+1,096
+0.4% +$24.8K 2.71% 14
2017
Q2 		$6.12M Sell
284,790
-8,754
-3% -$177K 2.52% 15
2017
Q1 		$4.99M Buy
293,544
+11,530
+4% +$201K 2.12% 19
2016
Q4 		$5.08M Buy
282,014
+52,206
+23% +$946K 2.31% 17
2016
Q3 		$4.83M Buy
229,808
+1,408
+0.6% +$34.9K 2.23% 18
2016
Q2 		$6.17M Sell
228,400
-296
-0.1% -$8.12K 2.83% 14
2016
Q1 		$6.17M Buy
228,696
+7,050
+3% +$189K 2.86% 13
2015
Q4 		$6.43M Buy
221,646
+11,340
+5% +$314K 3.11% 12
2015
Q3 		$5.68M Buy
210,306
+1,150
+0.5% +$32.6K 2.84% 15
2015
Q2 		$5.75M Buy
209,156
+2,124
+1% +$59.7K 2.8% 15
2015
Q1 		$5.49M Sell
207,032
-850
-0.4% -$19.6K 2.63% 16
2014
Q4 		$4.37M Sell
207,882
-50
-0% -$1.12K 2.12% 20
2014
Q3 		$4.99M Hold
207,932
– – 2.54% 18
2014
Q2 		$4.78M Sell
207,932
-1,558
-0.7% -$34.4K 2.45% 18
2014
Q1 		$4.82M Buy
209,490
+5,000
+2% +$107K 2.58% 17
2013
Q4 		$3.78M Buy
204,490
+10,600
+5% +$185K 2.04% 20
2013
Q3 		$3.53M Buy
193,890
+16,550
+9% +$278K 1.97% 20
2013
Q2 		$2.75M Buy
+177,340
New +$2.95M 1.76% 21

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Dillon & Associates's NVO Position: Q1 2026 in Review

Dillon & Associates reduced its Novo Nordisk (NVO) stake by 31% in Q1 2026, selling an estimated $4.49M and leaving 206,349 shares worth $7.63M. The position accounts for 1.05% of the portfolio, ranked #26.

Dillon & Associates first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.3M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Dillon & Associates held 206,349 shares of Novo Nordisk worth $7.63M as of Q1 2026.
  • Dillon & Associates sold 94,849 Novo Nordisk shares in Q1 2026, an estimated $4.49M.
  • Novo Nordisk made up 1.05% of Dillon & Associates's portfolio in Q1 2026, its #26 holding.
  • Dillon & Associates first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Dillon & Associates's Novo Nordisk position peaked at $40.3M in Q2 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Dillon & Associates's 13F filing for Q1 2026, filed 7 May 2026.